← Library
Cagrilintide / CagriSema
Research Use
Also known as AM833, Cagrilintide + Semaglutide
Function
Primary
Obesity (investigational)
Mechanism
Long-acting amylin receptor agonist — slows gastric emptying and suppresses postprandial glucagon; synergistic with GLP-1 (semaglutide).
Evidence
Clinical RCT (Limited)
Research
Phase 3 REDEFINE-1 reported ~22% weight loss
Dosing
Range
0.16–2.4 mg/week (mono); CagriSema 2.4/2.4 mg in trials
Frequency
Weekly
Route
Subcutaneous
Cycling
Continuous with stepwise titration.
Benefits
- ·Additive weight loss with GLP-1
- ·Improved satiety
- ·Glycemic control
Risks
- ·Nausea, vomiting
- ·Injection-site reactions
- ·Hypoglycemia (with insulin/SU)
Contraindications
- ·MTC / MEN-2 (when combined with semaglutide)
- ·Pregnancy
Regulatory
Investigational (Novo Nordisk, Phase 3 REDEFINE)
Functional Groups
Cited Works
- Garvey WT et al. CagriSema in Adults with Overweight or Obesity (REDEFINE-1). N Engl J Med. 2025.source